Announcements

Afferent Medical Solutions proudly announces its attainment of ISO 13485 certification from URS, underscoring the company's dedication to excellence and commitment to stringent quality standards. This achievement bolsters Afferent's position as a leader in developing advanced neuromodulation therapies for circulatory system diseases and other underserved therapeutic areas.

Afferent Medical Solutions has successfully concluded its Phase II trial, examining the efficacy of transcutaneous vagal nerve stimulation in acute ischemic stroke patients undergoing mechanical thrombectomy.

Afferent Medical Solutions secures a £650k RAIA Award to conduct a Phase II clinical trial investigating TanX's efficacy in post-stroke recovery. This funding will also facilitate the development of a remote patient monitoring solution,

Afferent Medical Solutions' SCRATCH-HTN trial, assessing the efficacy of auricular sensory stimulation for uncontrolled hypertension, secures MHRA approval, signaling a pivotal milestone in hypertension treatment innovation.

Afferent Medical Solutions celebrates the successful closure of its seed round funding, marking a significant milestone in its mission to innovate non-invasive medical solutions. With investor support, Afferent is poised to accelerate research and development efforts, driving forward its vision of revolutionizing healthcare through cutting-edge technology.

Afferent Medical Solutions secures a £1.1 million i4i award to fund its Phase II Clinical (SCRATCH-HTN) trial and develop its novel non-invasive device-based solution for uncontrolled hypertension. The trial will assess the safety, acceptability, and efficacy of autonomic neuromodulation using transcutaneous auricular sensory stimulation.

Afferent Medical Solutions Demonstrates Early Efficacy in Blood Pressure Reduction with Novel Non-Invasive Device